628 results on '"A. Kockaya"'
Search Results
152. Effect of Time in Therapeutic Range on Cost and Clinical Outcomes of Atrial Fibrilation Patients : A Cost-Consequences Analysis of Rivaroxaban Vs Warfarin For Turkey
153. PGI25 CLINIC AND ECONOMIC ANALYSIS FOR DIAGNISIS AND TREATMENT OF DIFFICULT BILE DUCT STONES WITH SINGEL OPERATOR CHOLANGIISCOPY IN TURKEY
154. PCV94 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN LITHUANIA
155. Comparison of qualitative and quantitative alterations caused by use of various fixatives in the myocardium
156. PRO75 PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY
157. PGI25 CLINIC AND ECONOMIC ANALYSIS FOR DIAGNISIS AND TREATMENT OF DIFFICULT BILE DUCT STONES WITH SINGEL OPERATOR CHOLANGIISCOPY IN TURKEY
158. PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY
159. PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY
160. PRO48 COST OF HAEMATOPOIETIC STEM CELL TRANSPLANT IN TURKEY
161. PSY33 HTA REVIEW OF DECISIONS FOR PRODUCTS INDICATED IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND LUPUS NEPHRITIS (N) IN UK, GERMANY, FRANCE, ITALY, SPAIN, CANADA AND TURKEY
162. PCV75 COST ANALYSIS OF COMPLICATIONS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN TURKEY
163. PBI42 ANALYSIS OF GENE AND CELL THERAPIES POLICIES IN EUROPEAN COUNTRIES
164. PCV94 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN LITHUANIA
165. PRO49 ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY
166. PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY
167. PNS159 PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY: ISPOR DATABASE SEARCH
168. PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY
169. PCV48 COST EFFECTIVENESS OF RIVAROXABAN IN CORONARY ARTERY DISEASE AND/OR PERIPHERAL ARTERY DISEASE FOR 5 DIFFEREN PATIENT SUB-GROUPS IN TURKEY
170. PNS188 ANALYSIS OF MARKET ACCESS AGREEMENTS IN TURKEY
171. PMH67 ANALYSIS OF PSYCHOTROPIC MEDICATIONS PRESCRIPTIONS IN TURKEY
172. Tangible Interactions with Acoustically Levitated Voxels
173. Tangible Interactions with Acoustic Levitation
174. Comparisons of some blood hematological levels and biochemical parameters in pregnant and non-pregnant Kangal shepherd dogs
175. Spectrum Detection Performance of HSTLBO Based Energy Sensing Algorithm in Cognitive Radio Networks
176. Will Translational Science Help Reduce Costs of Illness?
177. Kangal çoban köpeklerinin farklı hayvan sürülerinde gösterdikleri davranışsal ve fizyolojik değişkenlerin karşılaştırılması
178. Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey
179. Biallelic ZNF335 mutations cause basal ganglia abnormality with progressive cerebral/cerebellar atrophy.
180. Determination of Malondialdehyde (MDA), Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) Levels in Kangal Dogs with Maternal Cannibalism
181. Integration ability of urban free-ranging dogs into adoptive families' environment
182. PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY
183. PSY33 HTA REVIEW OF DECISIONS FOR PRODUCTS INDICATED IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND LUPUS NEPHRITIS (N) IN UK, GERMANY, FRANCE, ITALY, SPAIN, CANADA AND TURKEY
184. Comparison of behavioral and physiological responses of kangal dogs in different livestock flocks
185. PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS : A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEY
186. PCV65 - EXPERT ANALYSIS ON COST ANALYSIS OF MANAGEMENT OF CARDIOVASCULAR DISEASE CO-MORBIDITIES
187. PMU52 - COST IN COMPLEX ABDOMINAL OPERATIONS IN PUBLIC HEALTH INSURANCE PERSPECTIVE FOR TURKEY
188. Improving cost-efficiency at a hospital by showing the time-saving effect of using different neuromuscular blockers for short operations
189. Developing a Simulation-Based Training Program for the Prehospital Professionals and Students on the Management of Middle East Respiratory Syndrome
190. The Trend of the Prices Of New Marketed Drugs in Turkey
191. Impact Of Health Policy Changes on Unit Sales of 5 Top Selling Atc1 Phramaceutical Groups In Turkey
192. THE ROLE OF OBESITY SURGERY IN OBESITY TREATMENT IN TURKEY
193. Determination of some blood parameters during pregnancy and lactation periods in healthy Akkaraman Kangal ewes
194. Isolated Vertical Ophtalmoplegia and Mydriasis Due to Bilateral Midbrain Infarction
195. Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective
196. Determination of serum adenosine deaminase and xanthine oxidase activity in Kangal dogs with maternal cannibalism
197. Mobile Cardiac Monitorization Is A Cost-Effective Tool For The Diagnosis And Management Of Atrial Fibrillation Compared To Holter: A Cost Effectiveness Study In Turkey
198. Impact Of Health Policies On Catastrophic Health Expenditures In Turkey
199. Increasing Trend On Turkish Un-Licenced Medicine Market: A General Overview Analysis
200. Overview Of Innovative Medicine Sector In Turkey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.